| Bioactivity | AZD0095 is a selective and orally active MCT4 inhibitor (IC50: 1.3 nM). AZD0095 effectively inhibits the tumor growth in NCI-H358 xenograft in combination with Cediranib (HY-10205)[1]. | |||||||||
| Invitro | AZD0095 (0-50 µM) 抑制 NCI-H358 细胞 (MCT4 高表达) 的增殖，IC50 为 26 nM[1]。 | |||||||||
| In Vivo | AZD0095 (100 mg/kg, 口服，一天两次) 与 Cediranib (HY-10205) 联合使用抑制小鼠 NCI-H358 异种移植肿瘤的生长[1]。 Animal Model: | |||||||||
| Name | AZD0095 | |||||||||
| CAS | 2750001-23-9 | |||||||||
| Formula | C27H32N8O2 | |||||||||
| Molar Mass | 500.60 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Goldberg FW, et al. Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology. J Med Chem. 2022 Dec 16. |